Shares of Humacyte Inc. (HUMA) closed yesterday's trading at $7.71, which marks a year-to-date gain of over 160%.
This clinical-stage biotechnology platform company is involved in the manufacture of human acellular vessels, or HAVs, in varying sizes to address the significant unmet needs across multiple potential indications in vascular repair, reconstruction and replacement.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com